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Proteomic Analysis of the SH2Domain-
containing Leukocyte Protein of 76 kDa
(SLP76) Interactome*□S
Yacine Bounab‡§f, Anne-Marie-Hesse¶**f, Bruno Iannascoli‡§, Luca Grieco‡‡,
Yohann Couté¶**, Anna Niarakis‡‡, Romain Roncagalli§§¶¶a, Eunkyung Lieb,
Kong-Peng Lamc, Caroline Demangeld, Denis Thieffry‡‡, Jérôme Garin¶**,
Bernard Malissen§§¶¶a,e, and Marc Daëron‡§e
We report the first proteomic analysis of the SLP76 inter-
actome in resting and activated primary mouse mast
cells. This was made possible by a novel genetic approach
used for the first time here. It consists in generating
knock-in mice that express signaling molecules bearing a
C-terminal tag that has a high affinity for a streptavidin
analog. Tagged molecules can be used as molecular baits
to affinity-purify the molecular complex in which they are
engaged, which can then be studied by mass spectrometry.
We examined first SLP76 because, although this cytosolic
adapter is critical for both T cell and mast cell activation, its
role is well known in T cells but not in mast cells. Tagged
SLP76 was expressed in physiological amounts and fully
functional in mast cells. We unexpectedly found that
SLP76 is exquisitely sensitive to mast cell granular pro-
teases, that Zn2-dependent metalloproteases are espe-
cially abundant in mast cells and that they were respon-
sible for SLP76 degradation. Adding a Zn2 chelator fully
protected SLP76 in mast cell lysates, thereby enabling an
efficient affinity-purification of this adapter with its part-
ners. Label-free quantitative mass spectrometry analysis
of affinity-purified SLP76 interactomes uncovered both
partners already described in T cells and novel partners
seen in mast cells only. Noticeably, molecules inducibly
recruited in both cell types primarily concur to activation
signals, whereas molecules recruited in activated mast
cells only are mostly associated with inhibition signals.
The transmembrane adapter LAT2, and the serine/threo-
nine kinase with an exchange factor activity Bcr were the
most recruited molecules. Biochemical and functional
validations established the unexpected finding that Bcr is
recruited by SLP76 and positively regulates antigen-in-
duced mast cell activation. Knock-in mice expressing
tagged molecules with a normal tissue distribution and
expression therefore provide potent novel tools to inves-
tigate signalosomes and to uncover novel signaling mol-
ecules in mast cells. Molecular & Cellular Proteomics
12: 10.1074/mcp.M112.025908, 2874–2889, 2013.
Mast cells play critical roles in the initiation of IgE-depen-
dent allergic inflammation (1). They express high-affinity re-
ceptors for the Fc portion of IgE (FcRI)1, which are prototypic
immunoreceptors (2). Mast cell FcRI are composed of an
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iRTSV, Laboratoire de Biologie à Grande Echelle, Grenoble, France;
‡‡Institut de Biologie de l’Ecole Normale Supérieure (IBENS), UMR
ENS-CNRS 8197-Inserm 1024, Paris, France; §§Centre d’Immunologie
de Marseille-Luminy (CIML), Université Aix Marseille, UM2, Marseille,
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1 The abbreviations used are: FcRI, high-affinity receptors for the
Fc portion of IgE; ADAP, adhesion- and degranulation-promoting
adapter protein; Bcr, breakpoint cluster region protein; BMMC, Bone
marrow-derived mast cells; DAG, diacyl-glycerol; DNP, Dinitrophenyl;
ES, Embryonic stem; FDR, false discovery rate; Fyb, Fyn-binding
protein; Grap2, Grb2-related adapter protein 2; Grb2, growth factor
receptor-bound protein 2; HSA, human serum albumin; iBAQ, inten-
sity-based absolute quantification; IP3, inositol tris-phosphate; ITAM,
immunoreceptor tyrosine-based activation motif; Itk, IL-2-inducible
T-cell kinase; KI, knock-in; LAT, linker of activation of T cells; LCP2,
lymphocyte cytosolic protein 2, LM, laurylmaltoside; mAb, monoclo-
nal antibody; MAP, mitogen-activated protein; MS/MS, tandem mass
spectrometry; nanoLC, nano liquid chromatography; Nck, noncata-
lytic region of tyrosine kinase adapter protein; NTAL, non-T cell acti-
vation linker; OST, one-strep-tag; PAG, phosphoprotein associated
with glycosphingolipid-enriched microdomains; PLC, phospholipase
C; SH, Src homology; SHIP, SH2 domain-containing inositol 5-phos-
phatase; SKAP, Src kinase-associated phopshoproteins; SLP76, SH2
domain-containing leukocyte protein of 76 kDa; SDS, sodium dodecyl
sulfate; TCA, trichloroacetic acid; TCR, T cell receptor; WT, wild-type;
ZAP70, zeta-associated protein of 70 kDa.
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IgE-binding subunit, FcRI, and of two Immunoreceptor Ty-
rosine-based Activation Motif (ITAM)-containing subunits,
FcR and FcR (3). FcRI activate mast cells when receptor-
bound IgE antibodies are aggregated by a multivalent specific
antigen (4). FcRI aggregation triggers the constitution of
signalosomes in which positive and negative signals are gen-
erated, the integration of which determines quantitatively and
qualitatively the biological responses of the mast cell. The
composition of signalosomes is likely to evolve rapidly, as
molecules are sequentially recruited and as enzymes act on
their substrates. Determining the composition and describing
the dynamics of FcRI signalosomes is a major challenge for
who aims at understanding fundamental mechanisms of al-
lergy and at developing therapeutic tools for controlling aller-
gic reactions.
Mass spectrometry (MS)-based proteomics has emerged
as a powerful tool to study signaling networks. Indeed, it
enables large-scale analysis of stimulus-induced post-trans-
lational modifications (5–7). MS-based proteomics has also
been used to identify molecular partners that, at any given
time, are associated with a molecular bait of interest (8). This
bait carries an affinity-purification tag that markedly enhances
the efficiency with which it can be purified from a cell lysate (9).
The experimental conditions used may, however, limit the sig-
nificance of the result. Classically, baits are over-expressed in
cells that already express an untagged endogenous version of
the bait. Unbalanced expression of corresponding molecules
may profoundly alter biological responses. In some cases, baits
are expressed in cells that do not normally express the mole-
cule, where they may generate artifactual signalosomes. Finally,
baits are often expressed in transformed cells that can be grown
in high numbers, so that affinity-purified molecules are obtained
in amounts amenable to MS analysis (10, 11). Signaling path-
ways can be constitutively activated in these cells, because of
the expression of transforming oncogenes.
To overcome these problems, we generated a series of
knock-in (KI) mice expressing each a key signaling molecule
with a C-terminal one-strep-tag (OST) (12). OST-tagged mol-
ecules, as well as the molecules with which they interact can
be affinity-purified using beads coated with Strep-Tactin.
Strep-Tactin is a streptavidin derivative that has a high affinity
for OST (12). Affinity-purified molecules can then be identified
by MS. As documented here, this novel approach enables one
to study the interactome of endogenous OST-tagged mole-
cules that are present in physiological amounts, in nontrans-
formed cells by which they are normally expressed. Combin-
ing the interactomes of each tagged molecule analyzed
before and at different times after FcRI engagement should
ultimately make it possible to obtain a comprehensive dy-
namic functional map of the FcRI signalosome. As a proof-
of-concept, we studied the interactome of the Src Homology
(SH)2 domain-containing leukocyte protein of 76 kDa (SLP76)
(a.k.a. Lymphocyte cytosolic protein 2 or LCP2) in primary
mouse mast cells.
SLP76 is a cytosolic adapter that nucleates signaling com-
plexes generated by immunoreceptors (13). It contains an
N-terminal leucine Zip motif, a tyrosine-rich domain, a proline-
rich domain and a C-terminal SH2 domain. It is constitutively
associated with the growth factor receptor-bound protein 2
(Grb2)-related adapter protein 2 (Grap2, a.k.a. GADS) through
the interaction of its proline residues with one of the SH3
domains of Grap2 (14). SLP76 was mostly studied in T lym-
phocytes. Following T-cell receptor (TCR) engagement,
Grap2 binds to phosphorylated residues in the raft-associated
transmembrane adapter linker of activation of T cells LAT1.
SLP76-Grap2 complexes bind to phospholipase C (PLC)-1
(15), which stabilizes the recruitment of this enzyme by LAT1.
SLP76 tyrosines are phosphorylated by the cytosolic kinase
zeta-associated protein of 70 kDa (ZAP70) (16, 17), which
provides binding sites for the SH2 domains of Tec kinases
such as the IL-2-inducible T-cell kinase (Itk)(18), for the gua-
nine nucleotide exchange factors Vav-1 (17) and for adapters
such as the noncatalytic region of tyrosine kinase adapter
protein (Nck) (19). Molecules recruited by SLP76 launch the
intracellular propagation of signals leading to calcium mobili-
zation, the activation of Mitogen-activated protein (MAP) ki-
nases and, ultimately, full-blown T-cell responses.
SLP76 is also expressed by mast cells, and mast cell acti-
vation was markedly impaired in SLP76-deficient mice (20).
Surprisingly, signaling molecules that interact with SLP76 in
mast cells are not well characterized, and only a few papers
have been published on the subject. It was however shown
that the function of SLP76 in mast cells may not depend
entirely on LAT1, as it does in T cells. Indeed, LAT1 deficiency
could be, at least in part, compensated by the presence of
LAT2 in mast cells (21). LAT2 (a.k.a. non-T-cell activation
linker or NTAL) is a raft-associated tyrosine-rich transmem-
brane adapter related to LAT1. LAT2 is absent in resting T
cells, but present in B cells where it fulfills some of the
functions exerted by LAT1 in T cells. In mast cells, LAT1 and
LAT2 function as a pair of antagonistic molecules (22). The
role of SLP76 in mast cells cannot therefore be deduced from
that of SLP76 in T cells, and the mechanism(s) by which it
contributes to mast cell activation needs to be established.
We report here the first description of the SLP76 interac-
tome in resting and activated primary cultured mast cells. This
was done by combining high-affinity purification and label-
free quantitative proteomics in mast cells derived from KI
mice expressing SLP-76 with a C-terminal OST (Slp76OST/OST
mice). To reach this goal, we first unraveled and solved an
unexpected problem because of proteases contained in high
amounts in mast cell granules. We found that, compared with
the T-cell SLP76 interactome, the mast cell SLP76 interac-
tome is enriched in molecules involved in negative signaling.
We also found that the Breakpoint Cluster Region protein Bcr
is inducibly recruited by SLP76 and we could validate this
unexpected finding by showing that mast cells from Bcr-
deficient mice released less granular mediators than mast
The SLP76 Interactome in Mast Cells
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cells from wt mice. This is the first evidence that Bcr contrib-
utes to FcRI signaling.
EXPERIMENTAL PROCEDURES
Generation of Slp76OST Mice—A 6.2-kb genomic fragment contain-
ing exons 19–21 of the Slp76 gene was isolated from a BAC clone
(clone # RP23–216O16A; http://www.lifesciences.sourcebioscience)
of C57BL/6J origin. A OST-(Stop)2loxP-tACE-CRE-PGK-gb2-neo-
loxP cassette (23) was introduced at the 3 end of the Slp76 coding
sequence found in exon 21 using homologous recombination (24).
The targeting construct was then abutted to a thymidine kinase
expression cassette and linearized with FseI. JM8.F6 C57BL/6N ES
cells (25) were electroporated with the Slp76OST targeting vector and
selected in G418 and gancyclovir. Colonies were screened for ho-
mologous recombination by Southern blot. A neomycin-specific
probe was used to ensure that adventitious non-homologous recom-
bination events had not occurred in the selected ES clones. Appro-
priately targeted ES cells were injected into FVB blastocysts. After
germline transmission, screening for the deletion of the neo cassette
and the presence of the intended modification was performed by PCR
and Southern blot. All experiments were done in accordance with
French and European guidelines for animal care.
Cells—Bone marrow-derived mast cells (BMMC): BMMC were gen-
erated from femoral bone marrow harvested from Slp76OST/OST and
C57BL/6 (Slp76/) control mice (Charles River, France), from Bcr/
and littermate control (Bcr/) mice (a gift from Dr. Eunjoon Kim,
Korea Advanced Institute of Science and Technology, Daejeon, South
Korea), and from Dok-3/ and littermate control (Dok-3/) mice.
BMMC were propagated and cultured in OptiMEM (Invitrogen, St
Aubin, France) supplemented with 10% FBS (PAA Laboratories, Aus-
tria), 50 M 2-mercaptoethanol (Invitrogen), 100 g/ml Penicillin-
Streptomycin (Invitrogen), and 2 ng/ml recombinant murine IL-3 (Bio-
legend, San Diego, CA). Homogeneous populations of FcRI, Kit
cells were obtained after 3 weeks of culture. Thymocytes: Thymi were
collected from 6-week old C57BL/6 mice. Red cells were lysed in 10
mM Tris-HCL pH 7.5 and 142 mM NH4Cl.
Gene Expression Analysis—Three independent cultures were
seeded from the bone marrow of three individual mice and BMMC
were generated as described. Total RNA was extracted from resting
BMMC from the three replicate cultures using TRIzol reagent (In-
vitrogen, Invitrogen), and RNeasy mini kit from Qiagen (Courta-
boeuf, France). Purified total RNA was amplified by RT-PCR, and
transcripts were analyzed using the Applied Biosystems AB1700
microarrays (Carlsbad, California). We estimated the number of
proteases expressed in BMMC, according to the procedure de-
scribed in Supplementary Materials. A total of 539 out of the 685
annotated protease-coding transcripts were found to be repre-
sented in the AB1700 microarrays. Among them, 400 genes were
found expressed in BMMC with a confidence level greater than
90% (Fig. 3A). Supplemental Table S2 reports the results for the
expression of the 539 protease-coding genes covered by the
AB1700 microarrays.
Mast Cell Stimulation—BMMC were sensitized overnight with IgE
anti-DNP (mAb 2682-I) supernatant in complete culture medium (100
ng/ml IgE, final concentration). Cells were extensively washed with
HEPES-containing RPMI (Invitrogen), and challenged for various pe-
riods of time at 37 °C with 100 ng/ml DNP-HSA (Sigma-Aldrich, St.
Louis, MO) in the same medium.
-hexosaminidase Release—IgE anti-DNP-sensitized cells were
challenged for 20 min at 37 °C with the indicated concentrations of
DNP-HSA. -hexosaminidase released in cell supernatants was
measured using an enzymatic assay (26).
Cell lysates—Laurylmaltoside (LM) lysates: BMMC or thymocytes
were solubilized on ice for 10 min in lysis buffer consisting of 100 mM
Tris-HCL, pH 7.4 or pH 8.0, 150 mM NaCl, 2 mM MgCl2, 5% glycerol,
0.2% LM (Thermo Scientific, Courtaboeuf, France), and 25 U/ml
Benzonase (Merck, Darmstadt, Germany), supplemented with spe-
cific protease inhibitors (supplemental Table S4) or without. Protease
inhibitor cocktails were from Roche (Mannheim, Germany, Cat. #11
697 498 001), and from Sigma-Aldrich (Cat. #P8340. Phosphorami-
don (Cat. #R7385), EDTA and EGTA were from Sigma-Aldrich. SDS
lysates: BMMC or thymocytes were lysed by boiling at 90 °C for 5 min
in 1% SDS and 100 mM Tris-HCL pH 8.0. 25 U/ml Benzonase and 2
mM MgCl2 was added to SDS lysate that was left on ice for 10 min.
Western Blotting Analysis—LM and SDS cell lysates were centri-
fuged at 14,000 rpm for 15 min at 4 °C and supernatants were
electrophoresed on 4–12% Criterion XT precast gel (Bio-Rad,
Marnes-la-Coquette, France) using XT MOPS (Bio-Rad) running
buffer, and transferred onto nitrocellulose Hybond-P membranes
(Amersham Biosciences, Velizy-Villacoublay, France). Membranes
were saturated either with 5% BSA (Sigma-Aldrich) or 5% skimmed
milk (Régilait, Saint-Martin-Belle-Roche, France) for 1 h at room tem-
perature and blotted overnight at 4 °C with the indicated antibodies.
Rabbit anti-SLP76, anti-Akt, anti-Erk1/2, anti-phospho-Erk1/2, anti-
phospho-p38 and mouse anti-phospho-Tyrosine (P-Tyr-100) anti-
bodies were from Cell Signaling Technology (St-Quentin-en-Yvelines,
France). Rabbit anti-LAT1 and anti-phospho-LAT1, mouse anti-Vav,
rabbit anti-Sos antibodies were from Upstate Biotechnology (Lake
placid, NY). Goat anti-actin, mouse anti-PLC-1, anti-Dok-3 and anti-
SHIP1, Rabbit anti-Fyn, anti-Bcr, anti-phopsho-Bcr (pY177), anti-Lyn
and anti-phospho-PLC-1 antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). Mouse anti-LAT2 antibodies were from
Alexis Biochemical (Lausanne, Switzerland). Rabbit anti-PAG anti-
bodies were from ExBio (Praha, Czech Republic). Mouse anti-Grb2
and anti-phospho SLP76 antibodies were from BD Bioscience (Le-
Pont-de-Claix, France). Goat anti-Dok-3 antibody was from Abcam
(Paris, France). HRP-conjugated secondary antibodies were from
Santa Cruz Biotechnology. Mouse anti-phosphotyrosine antibodies
(mAb 4G10) were a gift from Dr. S. Latour (Inserm U.768, Hôpital
Necker, Paris, France). HRP was detected using an ECL kit (Thermo
Scientific).
Strep-Tactin Affinity-Purification—Four independent affinity purifi-
cations were performed on each set of samples (Slp76/ and
Slp76OST/OST BMMC challenged with antigen or without). One  108
Slp76/ or Slp76OST/OST BMMC were lysed for 10 min at 0 °C with
buffer containing 100 mM Tris-HCL, pH 8, 150 mM NaCl, 2 mM MgCl2,
5% glycerol, 0.2% LM, 1 mM sodium orthovanadate, 5 mM sodium
floride, 25 U/ml Benzonase and mast cells complete inhibitor mixture
(supplemental Table S4). Cell extracts were centrifuged at 14,000 rpm
for 15 min at 4 °C. Cleared lysates were incubated with 200 l
prewashed Strep-Tactin Sepharose beads (Iba BioTagnologies,
Goettingen, Germany) on a wheel for 1 h at 4 °C. Beads were washed
twice in 1 ml LM lysis buffer containing protease and phosphatase
inhibitors and three times with 1 ml LM buffer without inhibitors.
Beads were eluted 4 times with 150 l of 2.5 mM D-Biotin (Sigma-
Aldrich). Eluates were pooled and precipitated with TCA/Acetone.
Co-Immunoprecipitation—LM lysates of Slp76/ BMMC were in-
cubated for 2 h at 4 °C with protein-A Sepharose beads (GE Health-
care BioScience, Sweden) coated with anti-Bcr or anti-Dok-3 anti-
bodies. After washing with lysis buffer, the beads were boiled at 90 °C
with loading buffer for 5 min. Eluates were electrophoresed, and
Western blotted with anti-SLP76, anti-Bcr, anti-Dok-3, or anti-pY
antibodies.
Proteomic Analyses—(1) TCA precipitation. After elution, 125 l of
ice-cold TCA (Sigma-Aldrich) was added (final concentration 20%) to
each sample and the mixture was incubated 30 min on ice and
centrifuged at 20,000  g for 20 min at 4 °C. The supernatant was
removed and 600 l of TCA 10% was added to wash the pellet. The
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samples were centrifuged as above. The supernatant was removed
and 1 ml of ice-cold acetone (Sigma-Aldrich) was added to wash the
pellet. The samples were centrifuged as above. The acetone-contain-
ing supernatant was removed and the pellet was air-dried. The pellet
was suspended in 30 l of sample buffer, consisting of 25 mM
Tris-HCl, 4% glycerol, 2% SDS, 5% -mercaptoethanol, and 0.01%
bromphenol blue, and boiled for 5 min. Proteins were stacked by
SDS-PAGE in a 6 mm-thick band visualized by staining with Coo-
massie Brilliant Blue R-250 (Bio-Rad). (2) Protein digestion. The gel
band was manually excised and cut in pieces. The following sample
incubations were performed automatically using a Freedom EVO150
robot, (Tecan Traging AG, Switzerland). Gel pieces were washed by
six successive incubations of 15 min in 25 mM NH4HCO3 and in 25 mM
NH4HCO3 (Sigma-Aldrich) containing 50% (v/v) acetonitrile. Gel
pieces were then dehydrated with 100% acetonitrile and incubated
for 45 min at 53 °C with 10 mM DTT (Sigma-Aldrich) in 25 mM
NH4HCO3 and for 35 min in the dark with 55 mM iodoacetamide
(Sigma-Aldrich) in 25 mM NH4HCO3. Alkylation was stopped by add-
ing 10 mM DTT in 25 mM NH4HCO3 and mixing for 10 min. Gel pieces
were then washed again by incubation in 25 mM NH4HCO3 before
dehydration with 100% acetonitrile. For an overnight incubation at
37 °C, 0.2 g of modified trypsin (Promega, sequencing grade) in 25
mM NH4HCO3 was added to the dehydrated gel pieces. Peptides
were then extracted from gel pieces in three 15 min sequential ex-
traction steps in 30 l of 50% acetonitrile, 30 l of 5% formic acid
(Aristar, VWR International, UK) and finally 30 l of 100% acetonitrile.
The pooled supernatants were then dried under vacuum. (3) Nano-
LC-MS/MS analyses. The dried extracted peptides were resuspended
in a minimal volume of 5% acetonitrile and 0.1% trifluoroacetic acid
(Sigma-Aldrich) and analyzed twice by online nanoLC-MS/MS (Ulti-
mate 3000, Dionex and LTQ-Orbitrap Velos pro, Thermofisher, CA,
USA). The nanoLC method consisted in a 115-min gradient ranging
from 4% to 45% acetronitrile in 0.1% formic acid at a flow rate of 300
nL/min. Peptides were sampled on a 300 m  5 mm PepMap C18
precolumn and separated on a 75 m  250 mm C18 PepMap
column (Thermofisher). MS and MS/MS data were acquired using
Xcalibur (Thermofisher). Spray voltage and heated capillary were re-
spectively set at 1.4 kV and 200 °C. Survey full-scan MS spectra
(m/z  400–1600) were acquired in the Orbitrap with a resolution of
60,000 after accumulation of 106 ions (maximum filling time: 500 ms).
The 20 most intense ions from the preview survey scan delivered by
the Orbitrap were fragmented by collision induced dissociation (col-
lision energy 35%) in the LTQ after accumulation of 104 ions (maxi-
mum filling time: 100 ms). (4) Data analyses. RAW files were pro-
cessed using MaxQuant (27) version 1.3.0.5. Spectra were searched
against the Uniprot database (Mus musculus taxonomy 10090, 78810
sequences, July 2012 version) and the frequently observed contam-
inants database embedded in MaxQuant. Trypsin was chosen as the
enzyme and 2 missed cleavages were allowed. Precursor mass error
tolerances were set respectively at 20 ppm and 6 ppm for first and
main searches. Fragment mass error tolerance was set to 0.5 Da.
Peptide modifications allowed during the search were: carbamidom-
ethylation (C, fixed), acetyl (Protein N-ter, variable), oxidation (M,
variable) and deamidation (NQ, variable). Minimum peptide length
was set to seven amino acids. Minimum number of peptides, razor 
unique peptides and unique peptides were set to 1. Maximum false
discovery rates - calculated by employing a reverse database strat-
egy - were set to 0.01 at peptide and protein levels. Raw MS data
files, unfiltered protein groups and peptides tables have been up-
loaded in ProteomeXchange server (www.proteomexchange.org ac-
cession PXD000052). Identification and quantification data are also
provided for proteins in supplemental Table S7 and for peptides in
supplemental Table S8. Proteins identified as “contaminants,” “re-
verse,” and “only identified by site” were discarded from the list of
identified proteins. iBAQ values were calculated using MaxQuant as
previously described (28), from MS intensity of unique peptides. Data
coming from technical MS replicates were summed automatically. (5)
Statistical analyses. Normalization of protein iBAQ values was per-
formed on each sample using median calculated from proteins with
values in all 16 samples. Only proteins quantified with a minimum of
two unique peptides and for which a quantitative value could be
measured for the four affinity purifications replicates in at least one
condition were considered for the statistical analysis. The following
steps were performed using the Perseus toolbox (version 1.2.0.16)
available in the MaxQuant environment. After log2 transformation of
iBAQ values and data imputation (replacing missing values by normal
distribution as described in (29), protein expression differences were
identified using t-testing with a Permutation-based FDR to correct for
multiple hypothesis testing, S0 value set to 1 (30) and p value thresh-
old value set to 103. Only proteins with a significant t test result and
log2 ratio above 2 for enrichment in respectively nonactivated () and
activated () mast cells from Slp76OST/OST versus Slp76/ mice were
validated in resting and stimulated complex, respectively. Taking into
account that contaminant proteins may be not reproducible between
nonactivated and activated mast cells from Slp76/, we additionally
filtered proteins enriched in resting complex (with respect to stimu-
lated complex) if protein iBAQ in activated () mast cells from
Slp76/ mice was above protein iBAQ in nonactivated () mast cells
from Slp76OST/OST mice (respectively if protein iBAQ in nonactivated
() mast cells from Slp76/ mice was above protein iBAQ in acti-
vated () mast cells from Slp76OST/OST mice). The enrichment existing
between activated (OST) and nonactivated (OST) BMMC was also
t-tested with S0 value set to 1 (30), p value threshold value set to
102. Only proteins from resting or stimulated complex with a signif-
icant t test result and log2 ratio above two were further considered.
Sources of Information and Software Used for Protein Network
Analyses—Information on protein interactions was extracted from the
STRING (http://string-db.org) and PINA (http://cbg.garvan.unsw.edu.
au/pina/) databases. The software Cytoscape was used to construct
and visualize the SLP76 network (http://www.cytoscape.org). The
LAT2 and Bcr protein–protein interaction networks were obtained
from STRING database. We integrated experimentally verified inter-
actions and those described in databases. Information regarding
protease-coding genes has been extracted from Expasy web service
(http://expasy.org).
RESULTS
SLP76OST is Normally Expressed and Functional in Mast
Cells—Using gene KI in ES cells, a sequence corresponding to
the OST MS tag was introduced at the 3 end of the Slp76 gene.
Following germline transmission of the modified allele (denoted
as Slp76OST), KI mice homozygous for the Slp76OST allele were
established. Bone Marrow-derived Mast Cells (BMMC) were
generated from homozygous Slp76OST/OST KI mice and from
wild-type (wt) controls (Slp76/ mice) (Fig. 1A and 1B).
As judged by Western blotting of SDS lysates, Slp76OST/OST
BMMC contained similar amounts of SLP76 molecules as
Slp76/ BMMC (Fig. 1C), indicating that the presence of the
OST did not affect the level of SLP76 expression. When
sensitized with mouse IgE anti-DNP and challenged with
DNP-HSA, Slp76OST/OST BMMC released similar percentages
of the granular mediator -hexosaminidase as Slp76/
BMMC (Fig. 1D). Moreover, SLP76 and key signaling mole-
cules, including LAT1, PLC-1, and the MAPK kinases Erk1/2
and p38, which are terminally activated on FcRI engage-
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ment, were similarly phosphorylated in Slp76OST/OST and
Slp76/ BMMC (Fig. 1E). SLP76OST molecules are thus ex-
pressed at the same levels as wt SLP76 molecules in BMMC,
and the presence of the OST has no effect on antigen-induced
IgE-dependent FcRI signaling and subsequent mast cell
degranulation.
SLP76 is Degraded in BMMC Lysates by Mast Cell-Specific
Proteases—Because we aimed at performing affinity purifica-
tion of the SLP76OST bait under native conditions, BMMC
were solubilized with lysis buffer containing a mild nondena-
turing detergent, laurylmaltoside (LM), and a standard prote-
ase inhibitor mixture (Roche, Mannheim, Germany). Unex-
pectedly, wt SLP76, which was readily detected by Western
blotting in denaturing SDS lysates, could not be detected in
nondenaturing LM lysates. In contrast, all the other signaling
molecules examined were found in comparable amounts in
SDS and LM lysates (Fig. 2A). SLP76 was similarly undetect-
able in LM lysates of Slp76OST/OST BMMC (not shown) and in
Slp76/ BMMC lysates obtained with other mild nondena-
turing detergents such as octylglycoside, IGEPAL, Brij35 or
Triton X-100 supplemented with standard protease inhibitors
(supplemental Fig. S1). Similar amounts of SLP76 were, how-
ever, detected in both SDS and LM lysates from thymocytes
(Fig. 2B). The inability to detect SLP76 in LM lysates is there-
fore specific to mast cells.
Surprisingly, although SLP76 was undetectable in LM ly-
sates from nonstimulated BMMC sensitized with IgE antibod-
ies, it became increasingly detectable in LM lysates from the
same cells challenged with specific antigen for increasing
periods of time before lysis (Fig. 2C). As stimulated mast cells
degranulate within minutes, we hypothesized that granular
proteases might be responsible for SLP76 degradation. In-
deed, proteases contained in intact granules in nonstimulated
cells, but not in activated, degranulated mast cells, could be
FIG. 1. Expression and function of SLP76OST in BMMC. A, Diagram of the generation of Slp76OST/OST BMMC. B, Schematic representation
of SLP76OST molecules. The One-Strep-tag (OST) is composed of two 8-amino acid peptides (in red) separated by a 12-amino acid linker. C,
SLP76 expression in Slp76/ and Slp76OST/OST BMMC. BMMC were solubilized in SDS lysis buffer. Increasing amounts (1 , 2, and 3)
of lysates were electrophoresed and Western blotted with anti-SLP76 and anti-actin antibodies. D, -hexosaminidase release. IgE anti-DNP
sensitized Slp76/ and Slp76OST/OST BMMC were challenged with the indicated concentrations of DNP-HSA. -hexosaminidase was
measured in supernatant by an enzymatic assay. E, Intracellular signaling. IgE anti-DNP-sensitized Slp76/ and Slp76OST/OST BMMC were
challenged with or without DNP-HSA for 2 min and lysed in SDS lysis buffer. Equal amounts of proteins were electrophoresed and Western
blotted with indicated antibodies.
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freed on lysis and degrade SLP76 in mast cell lysates. To test
this hypothesis, we examined SLP76 in a nonactivated BMMC
LM lysate, in a thymocyte LM lysate and in a 1 to 1 mixture of
both. As expected from the above experiments, SLP76 was
observed in thymocyte LM lysate, but not in BMMC LM lysate.
Strikingly, SLP76 was also undetectable in the mixture (Fig.
2D). Mast cell-specific proteases present in BMMC could thus
degrade thymocyte-derived exogenous SLP76 molecules
and, therefore, mast cell-derived endogenous SLP76 mole-
cules following lysis in LM-containing buffer. We attempted to
overcome this problem by using other protease inhibitor
cocktails and by increasing their concentrations. SLP76 was
protected neither by increasing 10 times the concentration of
Roche protease inhibitors nor by using other mixtures of
inhibitors, whether commercially available (Sigma-Alrdich) or
custom-made (21) (Fig. 2E). Altogether, the above set of data
indicates that, when mast cells are lysed with mild nondena-
turing detergents, SLP76 is degraded by endogenous granu-
lar proteases that are resistant to conventional protease
inhibitors.
Zinc-Dependent Metalloproteases Account for SLP76 Deg-
radation in Mast Cell Lysates—To investigate the candidate
protease(s) responsible for SLP76 degradation, we performed
a transcriptomic analysis of BMMC. A total of 400 protease
transcripts were identified, belonging to the four main groups
of proteases. Serine proteases, cysteine proteases and
metalloproteases were the most abundant (Fig. 3A and
supplemental Table S1). The metalloprotease genes ex-
pressed in BMMC encode 176 metalloproteases (Fig. 3B and
supplemental Table S2), 73% of which are zinc-binding pro-
teins (Fig. 3B and supplemental Table S3). We noticed that,
although most protease inhibitor cocktails contain inhibitors
of proteases that depend on divalent cations such as Ca2
(EGTA) or Mg2/Mn2 (EDTA), they do not contain specific
inhibitors of Zn2-dependent metalloproteases (30). We
therefore investigated whether a Zn2 chelator would protect
SLP76 from degradation in mast cell lysates. We found that,
indeed, phenanthroline reduced the proteolysis of SLP76
when added to LM lysis buffer. Benzamidine, an inhibitor of
aspartic and serine proteases, also protected SLP76, albeit
less efficiently (Fig. 3C). The protection of SLP76 by phenan-
throline was much more efficient at pH 8.0 (supplemental
Fig. S2B) than at pH 7.4 (supplemental Fig. S2A). An in-
creased protection by the Roche mixture was also found at
high pH (supplemental Fig. S2C). When used at pH 8.0,
phenanthroline protected SLP76 more efficiently than any
other inhibitor.
FIG. 2. Proteolysis of SLP76 molecules in BMMC. (A, B) BMMC (A) and thymocytes (B) were solubilized in LM lysis buffer or in SDS lysis
buffer. Equal amounts of cell lysates were electrophoresed and Western blotted with the indicated antibodies. C, IgE anti-DNP-sensitized
BMMC were challenged with DNP-HSA for the indicated times and solubilized in LM lysis buffer. Equal amounts of BMMC lysates were
electrophoresed and Western blotted with anti-SLP76 and anti-actin antibodies. D, Equal amounts of proteins from a thymocyte LM lysate, a
BMMC LM lysate or a mixture of both were incubated for 10 min on ice, electrophoresed and Western blotted with anti-SLP76 antibodies. E,
BMMC were lysed in SDS lysis buffer or in LM lysis buffer containing no inhibitors (1), Roche mixture inhibitors 1 (2), Roche mixture inhibitors
10 (3), Sigma-Adlrich mixture 1 (4) or custom-made mixture inhibitors (21) (5). Lysates were electrophoresed and Western blotted with
anti-SLP76 and anti-actin antibodies.
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On the basis of these results, we devised a mast cell pro-
tease inhibitor mixture suitable for the biochemical analysis of
signaling molecules in mast cells. This “MC mixture” con-
tained E-64, AEBSF, chymostatin, antipain, bestatin, phenan-
throline, and benzamidine (supplemental Table S4). SLP76 was
dose-dependently protected when cells were lysed in LM buffer
containing increasing concentrations of MC mixture at pH 8.0.
Protection was complete when using the highest concentration
of MC mixture (supplemental Table S4) because, under these
conditions, comparable amounts of SLP76 were recovered in
LM lysates and in SDS lysates. Importantly, the level of protec-
tion observed at 10 min was fully retained after 90 min at 0 °C
(Fig. 3D). The establishment of these optimized lysis conditions
was an absolute requirement for an MS-based proteomic anal-
ysis of the SLP76 interactome in mast cells, because it is based
on the prior affinity purification of tagged SLP76 molecules from
LM lysates.
SLP76 and Interacting Proteins Can be Affinity-Purified
From Slp76OST/OST BMMC—Slp76OST/OST and Slp76/
BMMC were lysed in LM buffer pH 8.0 supplemented with the
MC mixture, and SLP76 was affinity-purified from lysates
using Strep-Tactin-coated Sepharose beads. Similar amounts
of lysates from Slp76OST/OST and Slp76/ BMMC were ap-
plied to the Strep-Tactin column (Fig. 4A, input). As expected,
no SLP76 was recovered from Slp76/ BMMC, whereas
most of the SLP76 molecules detected in lysate of Slp76OST/
OST BMMC were recovered from Strep-Tactin-coated beads
using four elutions steps with 2.5 mM D-Biotin, a ligand that
binds to Strep-Tactin with a higher affinity than the OST (Fig.
4A). Our protocol therefore enables the recovery of most of
the SLP76 species present in mast cell lysates.
To examine which proteins associate with SLP76 on mast
cell activation, Slp76OST/OST and Slp76/ BMMC were sen-
sitized with IgE antibodies and challenged with antigen or
without for 2 min. SLP76 was affinity-purified on Strep-Tactin-
coated beads, and eluates were analyzed by Western blot-
ting. Similar amounts of SLP76 were recovered in lysates from
challenged and unchallenged Slp76OST/OST BMMC, whereas
no SLP76 was recovered from Slp76/ BMMC. As expected,
the constitutively associated adapter protein Grap2 co-puri-
FIG. 3. A new protease inhibitor mixture prevents SLP76 degradation in mast cells. A, Families of proteases detected in BMMC by
transcriptomic analysis. B, Families of metal-binding protease encoded by BMMC metalloprotease genes. C, Screening protease inhibitors that
can protect SLP76 in BMMC lysates. BMMC were solubilized in LM lysis buffer containing specific protease inhibitors. Equal amounts of
lysates were electrophoresed and Western blotted with anti-SLP76 and anti-actin antibodies. D, Total protection of SLP76 degradation. BMMC
were solubilized in LM lysis buffer supplemented with a new custom-made inhibitor mixture for 10 min or 90 min. Equal amounts of lysates
were electrophoresed and Western blotted with anti-SLP76 and anti-actin antibodies.
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fied with SLP76OST, before and after antigen challenge.
SLP76OST was inducibly tyrosyl-phosphorylated on antigen
challenge, and two well-known SLP76 partners, Grb2 and
PLC-1, co-purified with phosphorylated, but not with non-
phosphorylated SLP76OST (Fig. 4B). Well-known activation-
inducible SLP-76 interactors could therefore be identified by
immunoblotting, following Strep-Tactin affinity purification of
LM lysates, provided that SLP76 degradation was prevented
by the protease inhibitor mixture that we specifically de-
signed. Biochemical conditions having been optimized, the
SLP76 interactome was investigated next by label-free quan-
titative proteomic analysis in Slp76OST/OST BMMC.
The SLP76 Interactome of Resting Mast Cells—Unlike clas-
sical biochemistry approaches, Strep-Tactin-based affinity
purification of SLP760ST enabled us to study proteins that
interact with SLP76 in resting cells. Indeed, molecules that
were co-purified from resting Slp76OST/OST BMMC, but not
from resting Slp76/ BMMC or in much lower amounts,
could be considered as being specifically and constitutively
associated with SLP76 in nonstimulated cells. The constitu-
tive SLP76 interactome is largely unknown, especially in
mast cells. The statistical treatment of iBAQ values coming
from MaxQuant processing of LC-MS/MS data correspond-
ing to four independent affinity purifications involving two
MS replicates revealed three proteins significantly enriched
in eluates from resting Slp76OST/OST BMMC compared with
eluates from resting Slp76/ BMMC (Fig. 5A, Table I and
supplemental Table S5, p value threshold set to 103 with
s0  1 and log2 ratio OST-/WT- 2). Among them, Grap2,
a well-known binding partner of SLP76, that could be seen
by Western blotting (Fig. 4B), was 500-fold more abundant
in eluates from Slp76OST/OST BMMC than in eluates from
Slp76/ BMMC. The Rho GTPase-activating proteins
RABE1 and RHG27 were enriched to a lesser extent in
eluates from Slp76OST/OST BMMC. RABE1 and RHG27 have
never been described before as SLP76 interactors.
The SLP76 Interactome is Markedly Enriched in Activated
Mast Cells—To determine the activation-induced SLP76 in-
teractome in mast cells, we performed two sets of compara-
tive MS analyses of proteins copurified with SLP76. First, we
compared the SLP76 interactome in Slp76OST/OST BMMC and
in Slp76/ BMMC, sensitized with IgE antibodies and chal-
lenged with antigen. The statistical treatment of iBAQ values
coming from MaxQuant processing of LC-MS/MS data cor-
FIG. 4. Strep-Tactin affinity purification
of functional SLP76 protein complexes
from BMMC lysates. A, StrepTactin
affinity-purification in LM lysates of
BMMC from Slp76/ (upper panel) and
Slp76OST/OST (lower panel) mice. Aliquots
from each step of the purification proce-
dure were Western blotted with anti-
SLP76 antibodies (Input 1%, FT; flow-
through 1%, washes 1%; eluates 10%).
The upper panels show a schematic of
the Strep-Tactin affinity-purification from
each cell. B, Copurification of known
interacting proteins of SLP76. IgE
anti-DNP-sensitized Slp76/ and
Slp76OST/OST BMMC were challenged
with DNP-HSA or without for 2 min and
lysed. Lysates were subjected to affinity-
purification with Strep-Tactin. Eluates
were electrophoresed and Western blot-
ted with anti-phosphotyrosine (pY), anti-
SLP76, anti-PLC-1, anti-Grap2, and
anti-Grb2 antibodies.
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responding to four independent affinity purifications involving
two MS replicates revealed 35 proteins significantly enriched
in eluates from activated Slp76OST/OST BMMC compared with
eluates from activated Slp76/ BMMC (p value threshold set
to 103 with s0  1 and log2 ratio OST/WT 2, Table II
and supplemental Table S5). This comparison aimed at dis-
criminating molecules that bound specifically to SLP76 from
molecules that bound nonspecifically to Strep-Tactin Sephar-
ose beads in activated mast cells. We then compared the
SLP76 interactome in Slp76OST/OST BMMC sensitized with
IgE antibodies and challenged with antigen or without for 2
min. This comparison aimed at identifying molecules that
FIG. 5. SLP76 protein-protein interaction network in resting and activated mast cells. A, Network view of the SLP76 interactome in mast
cells. White nodes: partners identified in resting cells; red nodes: additional partners identified in activated cells. Only proteins significantly
associated with SLP76 were included in the network. B, Comparison using Venn diagram of SLP76 partners identified in mast cells in the
present study and of previously published SLP76 partners. (C–E) Interactome networks of LAT2 (C), Bcr (D), and Dok-3 (E). Networks were
obtained from the STRING database.
TABLE I
SLP76 interactome in resting BMMC. Proteins were identified in four affinity purifications of SLP76OST complexes in resting cells. Listed
molecules were enriched at least fourfold in nonactivated SlpOST/OST compared to Slp/ BMMC (OST vs WT). The significance (p  103)
of enrichment (OST/WT ratio) was determined using student’s t-test. UniProt Accession numbers, protein symbols and molecular function
are also shown
Protein symbol Protein name UniProt Acc Function
Ratio
OST/WT
Resting BMMC
GRAP2 GRB2-related adaptor protein 2 O89100 Adapter Protein 513
RABE1 Rab GTPase-binding effector protein 1 O35551 GTPaseactivation 192
RHG27 Rho GTPase-activating protein 27 A2AB59 GTPaseactivation 72
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were recruited specifically by SLP76 on FcRI engagement
(as assessed by the OST/OST- ratio in Table II and supple-
mental Table S5).
Eighteen proteins were significantly (p value threshold set
to 102 with s0  1 and log2 ratio OST/OST- 2) and
specifically associated with SLP76 in activated Slp76OST/OST
BMMC (compared with nonactivated Slp76OST/OST BMMC)
(red nodes in Fig. 5A). In addition, the three SLP76 partners
identified in resting BMMC (white nodes in Fig. 5A) also co-
purified with SLP76 in activated BMMC. Grap2 remained
associated in comparable amounts, RHG27 was enriched
twofold, and RABE1 decreased more than half. Among the 21
proteins that constitute the SLP76 interactome of activated
BMMC (Fig. 5B), nine molecules were inducibly recruited with
a high statistical significance (p  103). Surprisingly, the
transmembrane adapter LAT2 (NTAL), which was not de-
tected in nonactivated Slp76OST/OST BMMC, was dramatically
enriched in activated Slp76OST/OST BMMC, much more than
any other molecule. In comparison, LAT1, which was also not
detected in nonactivated Slp76OST/OST BMMC, was detected
in activated Slp76OST/OST BMMC, but it was much less en-
riched (p  102) than LAT2. The molecular basis of this
dramatic difference remains to be determined. A limited num-
ber of proteins are known to interact with LAT2 (Fig. 5C). Two
unexpected molecules, the Breakpoint Cluster Region protein
(Bcr) and HIG1A, were also highly enriched. Bcr is a protein
with compound functions which interacts with numerous mol-
ecules (Fig. 5D). HIG1A is a HIG1-domain family member
whose function is not known. Other partners recruited with a
high statistical significance were also enriched but to a lower
extent. They included molecules known to be recruited by
SLP76 in activated T cells such as PLC-1, Shc1 and Grb2,
TABLE II
SLP76 interactome in activated BMMC. The proteins listed were recurrently identified in four affinity purifications of SLP76OST complexes in
activated cells. Listed molecules were enriched at least fourfold in activated SlpOST/OST (OST) compared to Slp/ BMMC (WT). The
enrichment was measured by the OST/WT ratio and its significance (p  103) determined using student’s t-test. The enrichment existing
between activated (OST) and nonactivated (OST) BMMC is also shown and its significance was determined using student’s t-test (at least
fourfold enrichment: **p  102, ***p  103). UniProt Accession numbers, protein symbols, and molecular function are also shown
Protein symbol
Activated BMMC Protein name UniProt Acc Function
Ratio
OST/WT OST/OST
LAT2 Linker for activation of T-cells family member 2 Q9JHL0 Adapter Protein 7146 4820***
BCR Breakpoint cluster region protein Q6PAJ1 Kinase/GTPasa activation 168 148**
HIG1A HIG1 domain family member 1A Q9JLR9 Unknown 144 104***
CDC23 Cell division cycle protein 23 homolog Q8BGZ4 Cell division 245 55
DC1I2 Cytoplasmic dynein 1 intermediate chain 2 O88487 Cytoskeleton regulation 15 38**
LAT1 Linker for activation of T-cells family member 1 O54957 Adapter Protein 36 37**
PLC1 1-phosphatidylinositol 4,5-bisphosphate
phosphodiesterase gamma-1
Q62077 Phospholipase 36 36***
SHC1 SHC-transforming protein 1 P98083 Adapter Protein 22 30***
DOK3 Docking protein 3 Q9QZK7 Adapter Protein 8,6 29***
SKAP2 Src kinase-associated phosphoprotein 2 Q3UND0 Src Kinase regulator 34 22***
SUCA Succinyl-CoA ligase ADP/GDP-forming	
subunit alpha, mitochondrial
Q9WUM5 Ligase 20 22**
GRB2 Growth factor receptor-bound protein 2 Q60631 Adapter Protein 18 16***
SKAP1 Src kinase-associated phosphoprotein 1 Q3UUV5 Src Kinase regulator 22 14***
HECD3 E3 ubiquitin-protein ligase HECTD3 Q3U487 Ligase 47 12
MSH2 DNA mismatch repair protein Msh2 P43247 DNA-binding 12 11**
CSTF1 Cleavage stimulation factor subunit 1 Q99LC2 mRNA processing 10 11**
FYB FYN-binding protein O35601 Adapter Protein 17 9.5**
BTK Tyrosine-protein kinase BTK P35991 Kinase 6,1 6.7**
PACS1 Phosphofurin acidic cluster sorting protein 1 Q8K212 Coat protein 13 5.4**
1433 14–3-3 protein eta P68510 Adapter Protein 26 4**
1433
 14–3-3 protein theta P68254 Adapter Protein 13 3,8
Q99M59 Interferon gamma inducible protein 47 Q99M59 Hydrolase activity 6,9 3,7
CLNK Cytokine-dependent hematopoietic cell linker Q9QZE2 Adapter Protein 40 3,7
VAV Proto-oncogene vav P27870 Guanine-nucleotide
releasing factor
10 3,3
MA2C1 Alpha-mannosidase 2C1 Q91W89 Mannosidase 13 3,1
1433 14–3-3 protein gamma P61982 Adapter Protein 45 3,0
1433 14–3-3 protein epsilon P62259 Adapter Protein 20 2,8
E9Q4N7 Protein Arid1b E9Q4N7 Unknown 28 2,4
1433 14–3-3 protein beta/alpha Q9CQV8 Adapter Protein 19 2,3
1433 14–3-3 protein zeta/delta P63101 Adapter Protein 15 2,0
RHG27 Rho GTPase-activating protein 27 A2AB59 GTPase activation 123 1,8
TP53B Tumor suppressor p53-binding protein 1 Q99LC2 mRNA processing 10 1,3
FA49B Protein FAM49B Q921M7 Unknown 29 1,2
GRAP2 GRB2-related adaptor protein 2 O89100 Adapter Protein 1086 0,9
RABE1 Rab GTPase-binding effector protein 1 O35551 GTPase activation 20 0,4
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but also molecules that were not previously identified as
SLP76 partners, such as the Src kinase-associated phopsho-
proteins SKAP1/2 and the cytosolic adapter Dok-3. Other
molecules that were statistically significantly recruited (p 
102) included LAT1, as already mentioned, a member of the
14–3-3 family, 14–3-3, the Fyn-binding protein Fyb, and the
Tec kinase BTK.
The cytosolic adapter Dok-3 interacts with several signaling
molecules among which the SH2 domain-containing inositol
5-phosphatase SHIP1 (INPP5D) (Fig. 5D). It belongs to the
same family as Dok-1, which is a major player in SHIP1-de-
pendent negative regulation of both B cell (31) and mast cell
(32) activation. Dok-3 was found in lysates of nonactivated
and activated BMMC, from Slp76OST/OST (Fig. 6A, upper
panel) and from Slp76/ (Fig. 6B, upper panel) mice. Con-
firming our AP-MS analysis, Dok-3 copurified with SLP76 in
activated cells in higher amount than in nonactivated cells
(Fig. 6A, lower panel). Conversely, SLP76 co-precipitated with
Dok-3 in activated cells more than in resting cells, and Dok-3
was markedly phosphorylated on antigen challenge. Notice-
ably, SHIP1 also co-precipitated with phosphorylated Dok-3
in activated cells (Fig. 6B, lower panel). To further investigate
the involvement of Dok-3 in FcRI signaling, we compared
-hexosaminidase released by BMMC from Dok-3/ mice
and by BMMC from Dok-3/ mice (Fig. 6C). Antigen-induced
mediator release was of the same magnitudes in Bcr/ and
Bcr/ BMMC sensitized with IgE (Fig. 6D). The deletion of
Dok-3 therefore did not detectably affect mast cell activation.
Because Bcr was an unexpected partner of SLP76, be-
cause it was inducibly recruited in high amounts on FcRI
engagement, because it was not previously linked to FcRI
signaling, because it interacts with numerous molecules and
FIG. 6. Validation of the SLP76-Dok-3 interaction in activated mast cells. A, Co-purification of Bcr with SLP76OST. Slp76OST/OST BMMC
sensitized with IgE anti-DNP were challenged with DNP-HSA () or without () for 2 min at 37 °C and lysed. Samples of whole cell lysates
(WCL) were Western blotted with anti-Dok-3 antibodies (upper panel). Remaining lysates were subjected to affinity-purification with Strep-
Tactin. Eluates were electrophoresed and Western blotted with anti-SLP76, anti-phosphotyrosine (pY), and anti-Dok-3 antibodies (lower panel).
B, Co-immunoprecipitation of SLP76 and SHIP1 with phosphorylated Dok-3. Slp76/ BMMC sensitized with IgE anti-DNP were challenged
with DNP-HSA () or without () for 2 min at 37 °C and lysed. Samples of whole cell lysates (WCL) were Western blotted with anti-Dok-3 or
anti-phospho-PLC-1 antibodies (upper panel). Remaining lysates were immunoprecipitated with anti-Dok-3 antibody. Eluates were electro-
phoresed and Western blotted with anti-Dok-3, anti-phosphotyrosine (pY), anti-SLP76 or anti-SHIP1 antibodies (lower panel). (C, D) Lack of
genetic evidence that Dok-3 is involved in FcRI signaling. Aliquots of BMMC from Dok-3/ and from Dok-3/ mice were lysed in SDS. whole
cell lysates (WCL) were Western blotted with anti-Dok-3 antibodies and, as positive controls, with anti-Bcr or anti-Grb2 antibodies (C). Aliquots
of the same cells were sensitized with IgE anti-DNP, and challenged with the indicated concentrations of DNP-HSA. -hexosaminidase was
measured in supernatant 10 min later (D).
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because it can exert multiple functions that may have a major
impact in FcRI signaling, we validated biochemically the
interaction between SLP76 and Bcr. We indeed found that
Bcr was similarly observed in lysates of nonactivated and
activated BMMC, whether from Slp76OST/OST (Fig. 7A, upper
panel) or from Slp76/ (Fig. 7B, upper panel and Fig. 7C)
mice. Bcr was co-purified with phospshorylated SLP76OST in
activated, but not in nonactivated Slp76OST/OST BMMC (Fig.
7A, lower panel). Conversely, SLP76 was co-immunoprecipi-
tated with Bcr in Slp76/ BMMC, and in higher amount in
activated cells than in nonactivated cells (Fig. 7B, lower
panel). Also, Bcr was inducibly phosphorylayed at Y178 on
antigen challenge (Fig. 7C). To further investigate the involve-
ment of Bcr in FcRI signaling, we compared -hexosamini-
dase released by BMMC from Bcr/ mice and by BMMC
from Bcr/ mice (Fig. 7D). Antigen-induced mediator release
was decreased in Bcr/ BMMC, compared with Bcr/
BMMC, sensitized with IgE (Fig. 7E). The deletion of Bcr
therefore impaired mast cell activation.
FIG. 7. Validation of the SLP76-Bcr interaction in activated mast cells. A, Co-purification of Bcr with SLP76OST. Slp76OST/OST BMMC
sensitized with IgE anti-DNP were challenged with DNP-HSA () or without () for 2 min at 37 °C and lysed. Samples of whole cell lysates
(WCL) were Western blotted with anti-Bcr antibodies. Remaining lysates were subjected to affinity-purification with Strep-Tactin. Eluates were
electrophoresed and Western blotted with anti-SLP76, anti-phosphotyrosine (pY), and anti-Bcr antibodies. B, Co-immunoprecipitation of
SLP76 with Bcr. Slp76/ BMMC sensitized with IgE anti-DNP were challenged with DNP-HSA () or without () for 2 min at 37 °C and lysed.
Samples of whole cell lysates (WCL) were Western blotted with anti-Bcr or anti-phospho-PLC-1 antibodies. Remaining lysates were
immunoprecipitated with anti-Bcr antibody. Eluates were electrophoresed and Western blotted with anti-Bcr, or anti-SLP76 antibodies. C,
Inducible Bcr phosphorylation in activated mast cells. BMMC sensitized with IgE anti-DNP were challenged with DNP-HSA () or without ()
for 2 min at 37 °C and lysed. Samples of whole cell lysates (WCL) were Western blotted with anti-Bcr, anti-pY178 Bcr, anti-phospho-SLP76
or anti-Grb2 antibodies. (D, E) Genetic evidence that Bcr is involved in FcRI signaling. Aliquots of BMMC from Bcr/ and from Bcr/
littermate control mice were lysed in SDS. whole cell lysates (WCL) were Western blotted with anti-Bcr antibodies and, as positive controls,
with anti-Dok-3 or anti-Grb2 antibodies (D). Aliquots of the same cells were sensitized with IgE anti-DNP, and challenged with the indicated
concentrations of DNP-HSA. -hexosaminidase was measured in supernatant 10 min later (E).
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DISCUSSION
We report here the first proteomic analysis of FcRI signal-
ing in primary mouse mast cells. Specifically, we describe the
SLP76 interactome in resting and in activated cultured mast
cells, using affinity purification coupled to label-free quantita-
tive proteomics. Data presented in this paper are the first
results of a large-scale program aiming at assembling a com-
prehensive dynamic map of signaling events triggered by
FcRI engagement in mast cells.
SLP76 has been extensively investigated following TCR
engagement in T cells, but much less following FcRI engage-
ment in mast cells. SLP76 deletion was however found to
profoundly affect IgE-induced mast cell activation (20). As
uncovered in the present study, one reason of this poor
knowledge on an adapter molecule that is essential for FcRI
signaling may be linked to its unexpected sensitivity to pro-
teolysis by mast cell granular proteases. We indeed found that
SLP76 was undetectable in LM lysates of nonactivated mast
cells, whereas it was readily detected in SDS lysates of the
same cells. No other intracellular molecule among the 14 that
we tested behaved like SLP76. This reminded us that, under
similar lysis conditions, SHIP1 was degraded by unknown
proteases in peritoneal cell-derived mast cells, a model of
mature serosal-type mast cells that are especially rich in
granular proteases, but not in BMMC (33). We noticed in the
present study that similar amounts of SLP76 were detected in
LM and SDS lysates of thymocytes and in LM lysates of
activated but not of nonactivated mast cells. To explain these
differences, we hypothesized that proteases contained in the
granules might digest SLP76 in lysates of nonactivated mast
cells, if granular membranes are disrupted by detergents. This
hypothesis was confirmed by experiments showing that thy-
mocyte-derived SLP76 was also degraded in a 1:1 mixture of
LM lysates of thymocytes and of nonactivated BMMC. Even if
restricted to SLP76, this proteolysis was a major obstacle for
our project. The SLP76 molecule is indeed functioning as a
scaffold protein, and its degradation is likely to dramatically
alter the signaling complex to be investigated. To circumvent
this problem, we undertook an extensive analysis of pro-
teases in BMMC.
Proteases were reported to account for up to 25% of total
proteins in mast cells (34). They are stored in granules under a
catalytically active form. They are released in the extracellular
medium under physiological conditions during antigen-induced
degranulation and they can have both pro-inflammatory effects
in IgE-induced allergic inflammation, and anti-inflammatory
effects in infection-associated inflammation (35). They can
also be released under nonphysiological conditions, when
granular membranes are solubilized by mild detergents during
cell lysis. Intracellular molecules are thus suddenly exposed to
large amounts of biologically active proteases that they nor-
mally never meet.
According to our transcriptomic study, more than a quarter
(28%) of proteases expressed in BMMC are metallopro-
teases. Among these, almost three quarters (73%) are Zn2-
dependent. Commercially available protease inhibitor cock-
tails, however, do not or poorly inhibit Zn2-dependent
metalloproteases. We found that adding a specific Zn2 ch-
elator to other inhibitors fully protected SLP76, even for pro-
longed periods of times (90 min at 0 °C) that are required for
affinity purification.
The lysis conditions defined in the present study enabled us
to analyze the SLP76 interactome, not only in activated mast
cells, but also in nonactivated mast cells. The unique tagged
SLP76 molecules that we developed via a KI approach and
used here enabled us to compare mast cells from Slp76/
and from Slp76OST/OST mice. Under these conditions, mole-
cules eluted from Strep-Tactin-coated beads in Slp76/
BMMC were considered as binding nonspecifically, i.e. as
background, whereas molecules eluted from Strep-Tactin-
coated beads in Slp76OST/OST BMMC, but not in Slp76/
BMMC, could be considered as binding specifically to SLP76
in resting mast cells. Three molecules were affinity-purified
along with SLP76OST from nonstimulated Slp76OST/OST
BMMC but not, or in much lower amounts, from nonstimu-
lated Slp76/ BMMC. These molecules corresponded to the
adapter protein Grap2 and to the two GTPase-activating pro-
teins, RABE1 and RHG27.
Among the molecules that displayed a statistically signifi-
cant enrichment (p  102) on FcRI engagement, one can
distinguish molecules that have been already described as
SLP76 partners in T cells and novel SLP76 partners that are
identified for the first time here in mast cells.
Six molecules interacted with SLP76 in both activated T
cells and activated mast cells. These were mostly adapter
molecules (LAT1, Grap2, Grb2, Shc1, Fyb) and one enzyme
(PLC-1). One notices that all these molecules concur to
intracellular pathways that lead to cell activation. LAT1 is an
essential scaffold protein that organizes the signalosomes
generated on TCR or FcRI engagement. The cytosolic adapt-
ers Shc, Grb2, and Grap2 are widely used by activating re-
ceptors and are involved in numerous signaling pathways.
Phospholipase C-1 (PLC-1) is a widely expressed major
signaling molecule, which, when activated on tyrosyl-phos-
phorylation, generates inositol tris-phosphate (IP3) and dia-
cyl-glycerol (DAG). IP3 triggers the efflux of Ca2 from endo-
thelial reticulum, leading to the influx of extracellular Ca2,
whereas DAG activates Protein Kinase C. By phosphorylating
PLC-1, the Bruton’s Tyrosine Kinase of the Tec family BTK
plays a critical role in the activation of this phospholipase.
SLP76 also associates with Clnk, a cytosolic adapter of the
SLP76 family which promotes TCR-dependent activation of T
cells (36, 37) and FcRI-dependent responses of mast cells
(38). Clnk deficiency, however, impaired neither TCR signaling
in T cells nor FcRI signaling in mast cells (39). Clnk interacts
with two phosphoproteins expressed in mast cell lines, Fyb,
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a.k.a. SLP76-associated protein of 130 kDa (SLAP-130) or
adhesion- and degranulation-promoting adapter protein
(ADAP), and SKAP1. These adapters can interact with the
SH2 domain of Src kinases to form a Clnk-Fyb-SKAP1 com-
plex in mast cells (40). Fyb and SKAP1 were among the
molecules that were recruited by SLP76 in mast cells, follow-
ing FcRI engagement (p  103 and p  102, respectively).
Some proteins previously reported to associate with SLP76 in
T cells were not found with a high enough statistical signifi-
cance in our MS-based proteomic analysis of the SLP76
interactome in mast cells. Lyn and Nck-1 could however be
detected by Western blot analysis among molecules that were
affinity-purified with SLP0ST (not shown). The reason for the
discrepancy lies in the severe filters used for establishing
statistical significance in our proteomic analysis (MS data and
statistical analysis of these results are shown in supplemental
Table S6).
Fifteen molecules that were inducibly recruited by SLP76
on FcRI engagement in mast cells have not been reported to
be recruited by SLP76 on TCR engagement in T cells. These
comprised adapter molecules (LAT2, 14–3-3F, CSTF1 and
Dok-3), a Tec family protein tyrosine kinase (Btk), Src kinase
regulators (SKAP1 and SKAP2), GTPase-activating molecules
(RABE1 and RHG37), a serine/threonine kinase with a gua-
nine-nucleotide exchange factor activity for Rho GTPases
(Bcr) (41), and molecules with poorly defined or unknown
functions (HIG1A, SUCA, MSH2, PACS1 and DC1I2). One
notices that most molecules with a known function that were
inducibly recruited in high amounts by SLP76 in mast cells,
but not in T cells, are associated with negative regulation.
The transmembrane adapter LAT2 was inducibly recruited
by SLP76 exceedingly more than any other molecules in
antigen-stimulated Slp76OST/OST BMMC. LAT2 is a well-
known antagonist of LAT1 in mouse mast cells, and LAT2-
deficient mice exhibited enhanced secretory responses on
FcRI engagement (42). The exact mechanisms by which
LAT2 inhibits mast cell activation is, however, largely un-
known (22), and it has been reported to interact with six
proteins only.
Dok-3, a cytosolic adapter of the Dok family is also asso-
ciated with negative regulation and was inducibly recruited in
the SLP76 interactome. This interaction of Dok-3 with SLP76
could be confirmed biochemically as Dok-3 co-purified with
SLP760ST. Conversely, SLP76 co-precipitated with Dok-3 in
wild-type cells. Noticeably, Dok-3 was dramatically phosphor-
ylated in activated mast cells. Dok-1 is well known to become
phopshorylated on immunoreceptor engagement in both B
cells (31) and mast cells (32), and to mediate the recruitment
of RasGAP which, by increasing the autocatalytic activity of
Ras-GTP, inhibits the Ras pathway. Dok-2 plays a similar role
as Dok-1 in T cells (43), but Dok-1 and Dok-3 were found to
have nonredundant roles in B cells (44). Dok-3 was found
among the proteins that are phosphorylated on FcRI en-
gagement in mouse mast cells (45). When tyrosyl-phospho-
rylated in B cells and macrophages, Dok-3 mediated the
membrane recruitment of SHIP1 and Csk, two molecules that
have inhibitory properties. Dok-3 over-expression reduced B
Cell Receptor-dependent B cell activation whereas the ex-
pression of Dok-3 the four C-terminal tyrosines of which were
mutated, i.e. rendered unable to bind to the SH2 domain of
SHIP1, enhanced B cell activation (46). We show here that
Dok-3 can also inducibly recruit SHIP1 on FcRI engagement
in mast cells as SHIP1 co-precipitated with phosphorylated
Dok-3 in activated mast cells. SHIP1 is a major negative
regulator of immunoreceptor signaling, and especially of
FcRI signaling (reviewed in (47)). The deletion of Dok-3,
however, had no detectable effect on mast cell degranulation,
probably because Dok-1, and possibly Dok-2, were sufficient
to recruit SHIP1.
The second most inducibly recruited molecule was the
Breakpoint Cluster Region protein Bcr. It was enriched almost
150 fold in eluates from antigen-stimulated Slp76OST/OST
BMMC, as compared with eluates from resting Slp76OST/OST
BMMC. Importantly, we could confirm the inducible interac-
tion of Bcr with SLP76 with biochemical techniques. Bcr was
indeed co-affinity-purified with SLP76OST in lysates of acti-
vated Slp76OST/OST BMMC, and SLP76 was co-immunopre-
cipitated with Bcr in lysates of activated Slp76/ BMMC.
Supporting a functional role of Bcr in FcRI signaling, we
found that it was inducibly phopshorylated at Y178 in acti-
vated mast cells. Brc was similarly found to be phosphory-
lated at Y177 on TCR engagement in human Jurkat cells (48).
Finally, we obtained a compelling evidence that Bcr positively
regulates IgE-dependent mast cell activation as mediator re-
lease was reduced in BMMC from Bcr-deficient mice. To our
knowledge, this is the first demonstration that Bcr is involved
in and contributes to FcRI signaling. Bcr binds to multiple
adapter molecules, including Grb2, Hck, Shc1, and Cbl as
well as Dok-1, Dok-2, and therefore, possibly Dok-3. One
notices several other interesting molecular partners in the Bcr
interactome that can be constructed from published data-
bases (Fig. 5D). These include Kit, which critically determines
the proliferation and differentiation of mast cells, molecules
that control cytokine receptor signaling such as Jak2 and
STAT5A/B, the exchange factors Sos and Vav, and, strikingly,
a whole cluster of small G proteins of the Rho and Rac families
that exert major cytoskeletal effects by controlling the dynam-
ics of actin. Bcr has itself a serine-threonine kinase activity.
Bcr is also a GTPase-activating protein for Rac1 and cdc42
and an exchange factor for Rho GTPases. Normally, the Bcr
exchange factor activity is auto-inhibited by flanking se-
quences (49). It is constitutively activated in the Bcr-Abl fusion
protein (41) that accounts for the transformation of myeloid
cells in chronic myeloid leukemia. The GTPase activity of Bcr
is positively regulated by a Protein Tyrosine Phosphatase
Receptor in neurons. Bcr is indeed highly expressed in the
central nervous system where it decreases dendrite formation
by negatively regulating actin polymerization in neurons (50).
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Along this line, the genetic ablation of Bcr and Abr, another
Rac/cdc42-specific GTPase-activating exchange factor, in-
creased cytoskeleton-dependent motility and phagocytosis in
primary macrophages (51).
In conclusion, the present work first describes the SLP76
interactome in primary mast cells and unravels that it mark-
edly differs from the SLP76 interactome previously described
in T cells. Our work also provides the first evidence that Bcr is
involved in FcRI-dependent mast cell activation. It also val-
idates OST-KI mice as powerful tools for the proteomic anal-
ysis of cell signaling. As SLP76OST was expressed with a
normal tissue distribution, it could be studied in nontrans-
formed mast cells. SLP76OST was expressed in mast cells
from Slp76OST/OST mice in similar amounts as wt SLP76 in
mast cells from Slp76/ mice. A unique advantage of the
present approach is that, unlike in cells transfected with cDNA
encoding a tagged molecule, no competition and no dilution
with endogenous nontagged molecules occurs in cells from
OST-KI mice as all molecules of interest are tagged. Impor-
tantly, OST-SLP76 was also functionally similar as wt-SLP76
because -hexosaminidase release and intracellular phos-
phorylations of a comparable magnitude were induced on
antigen challenge in Slp76OST/OST and Slp76/ mast cells
sensitized wit IgE antibodies. On the basis of these results,
one can apply the same approach to study the interactomes
of other key signaling molecules in mouse mast cells. One
expects not only to order known molecules in space and
time, and to untangle the complex network of their interac-
tions, but also to discover molecules not previously known
as being involved in mast cell activation and, ultimately, to
build up a comprehensive molecular map of the FcRI sig-
nalosome.
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